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Abstract
Background: Hepatocyte growth factor (HGF) is known to be involved in the resolution of pulmonary
inflammation and repair of acute lung injury. Legionella pneumonia is sometimes complicated by acute lung injury.
Our study aimed to determine the role of serum HGF levels in Legionella pneumonia.
Methods: Sera from patients with Legionella pneumonia (42 cases), other bacterial pneumonia (33 cases),
pulmonary tuberculosis (19 cases), and normal controls (29 cases) were collected. The serum HGF levels for each
serum sample were determined by sandwich ELISA. Clinical and laboratory data were collected by reviewing the
medical charts.
Results: Serum HGF levels were higher in patients with Legionella pneumonia than in those with other bacterial
pneumonia, pulmonary tuberculosis, and controls. The HGF levels were compared with white blood cell counts,
C-reactive protein, Alanine amino- transferase, and lactate dehydrogenase (LDH). The HGF levels were correlated to
serum LDH levels. Moreover, serum HGF levels were significantly higher in non-survivors than in survivors.
Conclusions: HGF levels increased in severer pneumonia caused by Legionella, suggesting that HGF might play a
significant role in the Legionella pneumonia.
Background
Hepatocyte growth factor (HGF) has been proved to be
a multi-functional peptide growth factor, which plays
important roles in lung development, lung inflammation,
and repair [1]. Possible sources of HGF within the lung
include bronchial epithelial cells, alveolar macrophages
[2], and neutrophils [3]. The role of HGF in pulmonary
infections has been studied in depth. Several studies
have convincingly demonstrated that plasma/serum
HGF levels become elevated in bacterial pneumonia
[4,5]. Serum HGF levels are considered to be associated
with the response of pneumonia to antimicrobials [6].
A study has previously shown that HGF is elevated in
pulmonary fluid in acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS) and that higher
HGF levels are associated with increased mortality [7].
Legionella spp. is a common causative pathogen of
pneumonia, which can be fatal if complicated with acute
lung injury (ALI) or acute respiratory distress syndrome
(ARDS) [8]. The bacterial etiology of community-
acquired pneumonia requiring ICU admission includes
Legionella species as well as Streptococcus pneumoniae.
However, the pathophysiology of fatal Legionella pneu-
monia remains unsolved. In this study, in order to clar-
ify the role of HGF in Legionella pneumonia, the serum
HGF concentrations in patients with Legionella pneu-
monia as well as other pulmonary infections were deter-
mined. We then evaluated the correlations between
HGF levels and other clinical indicators and outcomes.
Methods
Study population
Our study included 42 consecutive cases of Legionella
pneumonia diagnosed in our hospital. Further, 33 cases
with other bacterial pneumonia, 19 cases with active pul-
monary tuberculosis, and 29 age-adjusted control subjects
were also included in this study. The pathogens isolated
from the other bacterial pneumonia cases included Strep-
tococcus pneumoniae (12 cases), Hemophilus influenzae
(10 cases), Klebsiella pneumoniae (7 cases), Mycoplasma
* Correspondence: fhiga@med.u-ryukyu.ac.jp
Department of Infectious, Respiratory, and Digestive Medicine, Control and
Prevention of Infectious Diseases, Faculty of Medicine, University of the
Ryukyus, Okinawa 903-0215, Japan
Higa et al. BMC Infectious Diseases 2011, 11:74
http://www.biomedcentral.com/1471-2334/11/74
© 2011 Higa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.pneumoniae (4 cases), and others (3 cases). Control sub-
jects were healthy without any infections, lung diseases,
or liver diseases.
This study was approved by the University of the Ryu-
kyus Institutional Review Board. The need for informed
consent from each patient for inclusion in the study was
waived because of the retrospective approach of this
study, which caused no additional adverse events in any
of the subjects. However, prior informed consent had
been obtained from each patient before performing any
procedure or obtaining any sample.
Blood samples were obtained for conventional clinical
diagnosis from each patient. Bronchoalveolar fluids were
obtained when required for the diagnosis of Legionella
pneumonia. These samples were stored at -80°C until
further use. Medical chart reviews were used to obtain
information regarding the laboratory findings and clini-
cal outcome of each patient.
Diagnosis of pneumonia and tuberculosis
The diagnosis of pneumonia was based on the clinical
presentation (symptoms and physical examination),
chest X-ray findings, and laboratory data. The diagnosis
of Legionella pneumonia was confirmed by the detection
of Legionella by culture, elevation of antibody titers in
paired sera, and/or detection of its specific antigen in
the urine. The other pneumonia cases were diagnosed
based upon the bacteriological investigations (blood cul-
ture and culture of the expectorated sputa with satisfac-
tory quality for examination), pulmonary tuberculosis
was diagnosed following a positive smear test for acid-
fast bacilli as well as positive culture.
HGF determination
Sera were prepared conventionally and stocked at -80°C
until further investigation. The stock period was up to
years without freeze-thaw cycle. The HGF level for each
serum sample was determined by a sandwich ELISA
(R&D Systems, Minneapolis, MN) using recombinant
human HGF as a standard. The lowest detection limit
f o rH G Fw a s4 0p g / m L .T h i sk i td e t e c t sb o t ha c t i v e
form and pro-form of HGF. Inter- and intra-assay
reproducibilities are reported as 7.0% and 5.6%,
respectively.
Statistical methods
Data are reported as mean ± standard deviation (SD).
The logarithmic transformation of several data values
(HGF, white blood cell counts (WBC), and lactate dehy-
drogenase (LDH)) allowed Gaussian approximation
(demonstrated by the Kolmogorov -Smirnov and Sha-
piro-Wilk tests). Differences in the logarithmically trans-
formed values for HGF levels between multiple groups
were examined by using analysis of variance (ANOVA)
and Bonferroni’s multiple comparison test. Differences
between two groups were examined using unpaired
t-test with Welch’s correction and Mann-Whitney test.
The relationship between two parameters was deter-
mined by Pearson’s correlation coefficient test. These
tests were performed using statistical software programs
(Prism 4, Graphpad Software Inc., California; and SPSS
version 15.0J, SPSS Japan Inc., Tokyo). P <0 . 0 5w a s
considered statistically significant.
Results
Legionella pneumonia cases were noted more frequently
in males than in females; however, no difference was
noted with respect to the mean age or rate of known
liver disease as compared to other bacterial pneumonia
cases (Table 1). Average time interval between onset to
diagnosis (day of collecting samples) were 9.7 ± 5.8
days. Fourty-one among 42 Legionella pneumonia cases
had prior treatment with beta-lactams. After establish-
ment of diagnosis, macrolide, tetracycline, or quinolone
antimicrobials were used. Single case had concomitant
infection with Enterococcus facium and Prevotella inter-
media, who was survivor. In this study, the mortality of
Legionella pneumonia patients (19.0%) was higher than
that for patients with other bacterial pneumonia (5.5%),
but the difference was not statistically significant. Serum
Table 1 Characteristics of cases for this study
Legionella pneumonia Other bacterial pneumonia Pulmonary tuberculosis Control p
cases 42 36 19 27
age 58.9 + 12.0 58.3 + 18.2 56.7 + 16.4 54.2 + 19.1 n.s.
sex 37/ 5
a 21 / 15 10 / 9 18 / 11 0.004
a
outcome (alive/dead) 34 / 8 34 / 2 - - 0.097
known liver disease 2
b 2
b 0 0 n. s.
b
ALT 66.4 + 58.7
c 32.9 + 34.5
c 21.2 + 16.2
c - < 0.01
c
LDH 807.3 + 748.9
d 218.4 + 88.6
d 239.1 + 302.4
d - < 0.001
d
a: M/F ratio was significant higher in Legionella pneumonia than in other bacterialpneumonia.
b: n.s. not significant.
c, d: ALT and LDH were significantly higher in Legionella pneumonia cases than in other bacterial pneumonia and pulmonary tuberculosis.
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Legionella pneumonia cases than other bacterial pneu-
monia cases and pulmonary tuberculosis cases (Table 1).
Serum HGF levels were significantly elevated in Legio-
nella pneumonia cases, other bacterial pneumonia cases,
and pulmonary tuberculosis cases as compared to those
in normal subjects (Figure 1). Further, the serum HGF
levels were significantly higher in Legionella pneumonia
cases than those in other bacterial pneumonia cases
(Figure 1). To examine the influence of HGF levels by
gender, the serum HGF levels in male and female
patients of pneumonia and control subjects were com-
pared; however, no significant differences were noted
(data not shown). The male predominance of Legionella
pneumonia did not influence the HGF levels.
Next, serum HGF levels were compared with the clini-
cal indicators of disease activity, i.e., WBC counts,
C-reactive protein (CRP), PaO2/FiO2 ratio, LDH, and
ALT levels (Table 2). Serum HGF levels were signifi-
cantly correlated with LDH levels (Table 2). Serum HGF
levels were not associated with the interval between
onset of disease and the date when serum was obtained
(data not shown). Extension of pulmonary lesion did not
affect HGF levels. A comparison of serum HGF levels
between survivors and non-survivors among Legionella
pneumonia revealed that HGF levels and LDH activities
of non-survivors were significantly higher than those
of survivors (Figure 2), while WBC counts and CRP
levels were not associated with the clinical outcomes
(Figure 2). HGF levels in non-suvivors of other bacterial
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Figure 1 Serum HGF levels in patients with Legionella pneumonia, other bacterial pneumonia, pulmonary tuberculosis, and controls.
Each symbol represents HGF levels at admission in each case. Analysis was performed by ANOVA and Bonferroni’s test using normalized data by
logarithmic transformation. *: p < 0.01, **: p < 0.001.
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Page 3 of 6pneumonia (2 cases) were 5,183 pg/mL and 4,257 pg/
mL. Among two cases of Legionella pneumonia with
known liver diseases, one case was a non-survivor and
HGF level was 9,584 pg/mL. Another case was a survi-
vor and HGF level was 21,008 pg/mL.
Discussion
Our study confirmed that serum HGF levels were ele-
vated in pulmonary infections as reported previously
[5,6,9]. However, our findings offered a new perspective
by comparing serum HGF levels in pulmonary infections
due to different pathogens. Serum HGF levels in
patients with Legionella pneumonia were higher than in
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Figure 2 Comparison of serum HGF and various bio-indicators (white blood cell counts, C-reactive protein, and LDH) in non-survivors
and survivors of Legionella pneumonia. Analysis was performed by the unpaired t-test with Welch’s correction.
Table 2 Association of HGF and other clinical indicators
biomarkers correlation coefficient ( r ) r
2 p
a
HGF WBC 0.207 0.043 0.195
HGF CRP 0.201 0.040 0.226
HGF PaO2/FiO2 -0.155 0.024 0.345
HGF LDH 0.538 0.289 0.001
HGF ALT 0.232 0.054 0.160
WBC CRP 0.422 0.178 0.009
LDH ALT 0.474 0.225 0.003
a: Association of Log(HGF) and each item was analyzed by Peason’s
coefficient test.
HGF: hepatocyte growth factor, WBC: white blood cell count, CRP: C-reactive
protein, LDH: lactate dehydrogenase, ALT: alanine aminotransferase.
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this study, the differences in the clinical characteristics
of Legionella pneumonia and other bacterial pneumonia
pertained to mortality and the male/female ratio. The
mortality noted for patients with Legionella pneumonia
in this study (19.0%) was similar to that in previous
reports, i.e., 5-20% [10-12]. The mortality noted for
patients with other bacterial pneumonia in this study
(5.5%) was similar to the report of a huge cohort study,
i.e., 5.2% [13]. Therefore, the mortality for each group
was considered typical. This study showed that HGF
levels did not differ with gender. In present study, LDH
and ALT activity was higher in Legionella pneumonia
than other bacterial pneumonia and pulmonary tubercu-
losis. Higher LDH suggested severer organ damages and
higher ALT suggested more frequent liver dysfunction.
The factors influencing increased serum HGF levels in
Legionella pneumonia might include severer form of the
pneumonia and complication of liver dysfunction.
The results of previous studies evaluating the relation-
ship between HGF levels and clinical outcomes seems to
be controversial. One study demonstrated that serum
HGF levels were lower in severe pneumonia than in non-
severe pneumonia [14]. In the study, however, the cause
of death include myocardial infarction (4 cases among 10
non-survivors). On the other hand, HGF levels in pul-
monary edema fluids from non-survivors were noted to
be higher than those in survivors of acute lung injuries
[7]. Another study shows that serum HGF levels as a use-
ful indicator of prognosis in inflammatory pulmonary dis-
eases [15]. Present study revealed that in patients with
Legionella pneumonia, serum HGF levels were higher in
non-survivors than in survivors. Non-survivors were com-
plicated by acute lung injury. Different cause of death
might cause the discrepancy between several studies.
Serum HGF levels were correlated with LDH activity.
The ratio of HGF/LDH seemed to be lower in non-
survivors than in survivors (Figure 3). This finding did
not achieve statistic significance, but our speculation
based on this finding is that HGF works to repair the
injury of lung and other organs, and insufficient HGF
production in severe pneumonia might be associated
with poor outcome. This would be worthwhile for
further studies for confirmation. Other biomarkers
(WBC counts and CRP) at the time of diagnosis were
not associated with the clinical outcome.
Conclusions
In conclusion, our study showed that HGF levels
increased in severer pneumonia caused by Legionella,
and suggested that HGF might play a significant role in
the Legionella pneumonia. Further studies that investi-
gate the precise role of HGF in severe Legionella pneu-
monia are warranted.
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